Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07138014) titled 'FHND1002 for ALS Treatment: Phase 2' on Aug. 15.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Condition: Amyotrophic Lateral Sclerosis (ALS)

Intervention: Drug: FHND1002 100mg Drug: FHND1002 200mg

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 1, 2025

Target Sample Size: 180

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07138014

Published by HT Digital Content Services wi...